

# OIE Reference Laboratory Reports Activities

## *Activities in 2019*

**This report has been submitted : 2020-01-07 11:08:37**

|  |                                    |
|--|------------------------------------|
| <b>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</b> | Swine influenza                    |
| <b>Address of laboratory:</b>  | Via Bianchi 9 25124 Brescia ITALY  |
| <b>Tel.:</b>   | +39 (0)52129.37.33                 |
| <b>Fax:</b>  | +39 (0)52129.35.38                 |
| <b>E-mail address:</b>   | chiara.chiapponi@izsler.it         |
| <b>Website:</b>  |                                    |
| <b>Name (including Title) of Head of Laboratory (Responsible Official):</b>                | Dr. Piero Frazzi                   |
| <b>Name (including Title and Position) of OIE Reference Expert:</b>                        | tbd Dr. Chiapponi Chiara Biologist |
| <b>Which of the following defines your laboratory? Check all that apply:</b>               | Governmental                       |

**ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards**

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test                         | Indicated in OIE Manual (Yes/No) | Total number of test performed last year |                 |
|---|----------------------------------|--|-----------------|
|   |                                  | Nationally                               | Internationally |
| Indirect diagnostic tests               |                                  |  |                 |
| Heamoagglutination inhibition test      | yes                              | 11432                                    | 1948            |
| Direct diagnostic tests                 |                                  |  |                 |
| Real-time PCR M gene                    | yes                              | 1990                                     |                 |
| Egg isolation                           | yes                              | 125                                      |                 |
| Cell culture isolation                  | yes                              | 230                                      |                 |
| PCR for IAV-S subtyping                 | yes                              | 159                                      |                 |
| Full genome sequencing of IAV viral RNA | no                               | 144                                      | 60              |

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.  
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Swine influenza - Chiapponi Chiara - italy

| Type of reagent available       | Related diagnostic test            | Produced/ provide | Amount supplied nationally (ml, mg) | Amount supplied internationally (ml, mg) | No. of recipient OIE Member Countries | Region of recipients   |
|---------------------------------|------------------------------------|-------------------|-------------------------------------|--|---------------------------------------|--|
| SWINE INFLUENZA ANTIGEN H1N2    | HI TEST                            | produced          | NONE                                | NONE                                     | N/A                                   | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input type="checkbox"/> Europe<br><input type="checkbox"/> Middle East            |
| SWINE INFLUENZA ANTIGEN H1N1    | HI TEST                            | produced/provided | 55 ml                               | NONE                                     | 1                                     | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input checked="" type="checkbox"/> Europe<br><input type="checkbox"/> Middle East |
| SWINE INFLUENZA ANTIGEN H1N1PDM | HI TEST                            | produced          | NONE                                | NONE                                     | N/A                                   | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input type="checkbox"/> Europe<br><input type="checkbox"/> Middle East            |
| SWINE INFLUENZA ANTIGEN H3N2    | HI TEST                            | produced          | NONE                                | 4 ml                                     | 1                                     | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input checked="" type="checkbox"/> Europe<br><input type="checkbox"/> Middle East |
|                                 |                                    |                   |                                     |  |                                       | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input type="checkbox"/> Europe<br><input type="checkbox"/> Middle East            |
| Hyperimmune serum H1N1          | haemoagglutination inhibition test | produced          | NONE                                | NONE                                     | N/A                                   | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input type="checkbox"/> Europe<br><input type="checkbox"/> Middle East            |

|  |                                    |                       |         |      |     |  |
|--|------------------------------------|-----------------------|---------|------|-----|--|
| Hyperimmune serum H3N2                   | haemoagglutination inhibition test | produced              | NONE    | NONE | N/A | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input type="checkbox"/> Europe<br><input type="checkbox"/> Middle East            |
| Hyperimmune serum H1N2                   | haemoagglutination inhibition test | produced              | NONE    | NONE | N/A | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input type="checkbox"/> Europe<br><input type="checkbox"/> Middle East            |
| Hyperimmune serum H1N1pdm                | haemoagglutination inhibition test | produced              | NONE    | NONE | N/A | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input type="checkbox"/> Europe<br><input type="checkbox"/> Middle East            |
| RNA virus A/swine/Italy/115269/2019 H3N2 | PCR                                | produced and provided | 0.05 ml | NONE | 1   | <input type="checkbox"/> Africa<br><input type="checkbox"/> Americ as<br><input type="checkbox"/> Asia and Pacific<br><input checked="" type="checkbox"/> Europe<br><input type="checkbox"/> Middle East |

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

***ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases***

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

**ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries**

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

| Name of OIE Member Country seeking assistance | Date (month) | No. samples received for provision of diagnostic support | No. samples received for provision of confirmatory diagnoses |
|---|--------------|--|--|
| CYPRUS  | July         | 29   | 0  |
| CYPRUS  | August       | 30   |  |
| GREECE  | January      | 31   |  |
| GREECE  | February     | 115  |  |
| GREECE  | April        | 77   |  |
| GREECE  | May          | 35   |  |
| GREECE  | July         | 83   |  |
| GREECE  | September    | 127  |  |
| GREECE  | October      | 49   |  |
| SPAIN   | July         | 6  |  |
| SPAIN   | October      | 37   |  |
| SPAIN   | November     | 58   |  |

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

| Name of the OIE Member Country receiving a technical consultancy | Purpose  | How the advice was provided |
|--|--|-----------------------------|
| SPAIN  | To obtain full genome sequences of swine influenza viruses | Protocol sent by email      |
| SERBIA   | To analyze genetic data                                    | paper                       |

**ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations**

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

| Title of the study                        | Duration  | Purpose of the study   | Partners (Institutions)  | OIE Member Countries involved other than your country                                  |
|---|-----------|--|--|--|
| International swine Influenza Network     | annual    | Supported by IDT, Germany  | FLI, Riems, Germany; DTU, Copenhagen, Denmark; CReSA, Barcelona, Spain; ANSES, Ploufragan, France; IZSVE, Padua, Italy; IZSLER, Brescia, Italy; APHA, Weybridge, UK; IDT, Dessau, Germany; Warsaw University, Warsaw, Poland | DENMARK<br>FRANCE<br>GERMANY<br>POLAND<br>SPAIN<br>UNITED KINGDOM                      |
| Risk assessment for influenza D in Europe | 2018-2019 | The objective is to develop an integrated approach to assess the emergence threat associated with influenza D viruses' circulation in Europe. By promoting transfer and exchange of knowledge and expertise between the partners we will pave the way towards scientific based decision-making and development of effective strategies for diagnosis and disease control | INRA,Utrecht University, Faculty of Veterinary Medicine Université de Liège : Luxembourg Institute of Health National Veterinary Institute, IZSLER, Italy  | FRANCE<br>LUXEMBOURG<br>SWEDEN<br>THE NETHERLANDS                                      |
| Swine Influenza Viruses OFFLU             | 2019      | Exchange scientific data about animal influenza viruses within the network   | ANSES (France), APHA (United Kingdom), DTU (Denmark), IZSLER (Italy), NVRI (Poland/Slovakia)UGhent (Belgium/Netherlands), IZSVE (Italy), UAB (Spain) and SVA (Sweden)  | BELGIUM<br>DENMARK<br>FRANCE<br>GERMANY<br>POLAND<br>SPAIN<br>SWEDEN<br>UNITED KINGDOM |

**ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases**

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

**13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 1

1. Mauro Delogu , Claudia Cotti , Gabriele Vaccari , Elisabetta Raffini , Matteo Frasnelli , Sandro Nicoloso , Vanessa Biacchessi , Arianna Boni , Emanuela Foni , Maria R Castrucci , Maria A De Marco. Serologic and Virologic Evidence of Influenza A Viruses in Wild Boars ( Sus Scrofa) From Two Different Locations in Italy-J Wild Dis 55 (1), 158-163. Jan 2019

b) International conferences: 2

1. Ian H. Brown, Pauline M. van Diemen, Alexander Byrne, Andrew Ramsay, Samantha Watson, Alejandro Nunez, Ana Moreno, Chiara Chiapponi, Emanuela Foni, Sharon M. Brookes and Helen E. Everett. Assessment of zoonotic transmission of swine influenza A viruses from pigs to naïve or vaccinated ferrets. Options for the control Of Influenza X.

2. Moreno Ana, Baioni Laura, Davide Lelli, Foni Emanuela, Prosperi Alice, Merenda Marianna, Faccini Silvia, Luppi Andrea, Alborali Giovanni, Salogni Cristian, Lavazza Antonio, Chiapponi Chiara. Reassortment patterns in pigs involving swine influenza A and 2009 Pandemic H1N1 viruses. 11th International Global Virus Network Meeting. Barcelona-Spain.2019

c) National conferences: 3

1. A. Prosperi, S. Faccini, M. Merenda, A. Amorico, A. Moreno, C. Rosignoli, E. Pariani, C. Galli, P. Affanni, M.E. Colucci, E. Foni, A. Luppi, C. Chiapponi: SURVEILLANCE AMONG ORTHOMYXOVIRUSES (IAV, IBV, ICV, IDV) IN ITALY (2014-2018). 3RD National Congress of the Italian Society for Virology – One Virology One Health, Padova, 10-12 Settembre 2019

2. Prosperi A., Faccini S., Merenda M., Zanni I., Baioni L., Gabbi V., Amorico A., Moreno Martin A.M., Rosignoli C., Pariani E., Galli C., Affanni P., Colucci M.E., Foni E., Luppi A., Chiapponi C.: SURVEILLANCE AMONG ORTHOMYXOVIRUSES (IAV, IBV, ICV, IDV): A DIAGNOSTIC APPROACH. XIX Congresso Nazionale S.I.Di.L.V. Matera, 23-25 Ottobre 2019.

3. Chiapponi C., Faccini S., Moreno A., Alborali G.L., Merenda M., Prosperi A., Luppi A., Amorico A., Baioni L., Zanni I., Manfredi R., Foni E. STUDIO SULLA CIRCOLAZIONE DI VIRUS INFLUENZALE TIPO A, B, C E D NEGLI ALLEVAMENTI SUINI NEL NORD ITALIA. CARATTERIZZAZIONE DEI VIRUS CIRCOLANTI NEGLI ANNI 2016-2018. SIPAS.

d) Other:

(Provide website address or link to appropriate information) 1

Data from swine influenza surveillance in Italy were provided as contribution to the 2019 OFFLU meeting. [http://www.offlu.net/fileadmin/home/en/meeting-reports/pdf/SIV\\_2019/Meeting\\_summary\\_final.pdf](http://www.offlu.net/fileadmin/home/en/meeting-reports/pdf/SIV_2019/Meeting_summary_final.pdf)

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries****To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

- a) Technical visits: 4
- b) Seminars: 0
- c) Hands-on training courses: 0
- d) Internships (>1 month): 0

| Type of technical training provided (a, b, c or d) | Country of origin of the expert(s) provided with training | No. participants from the corresponding country |
|--|---|---|
| a  | Italy   | 1   |
| a  | Sweden  | 2   |
| a  | Spain   | 1   |

**ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned**

15. Does your laboratory have a Quality Management System?

Yes

| Quality management system adopted | Certificate scan (PDF, JPG, PNG format) |
|-----------------------------------|---|
| EN ISO/IEC 17025:2005             | Accredia_Cert_2019.pdf                  |

16. Is your quality management system accredited?

Yes

| Test for which your laboratory is accredited | Accreditation body |
|--|--------------------|
| Matrix (M) gene PCR                          | ILAC-MRA_Accredia  |

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4*)



**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

| Purpose of the proficiency tests: <sup>1</sup>   | Role of your Reference Laboratory (organiser/participant) | No. participants | Participating OIE Ref. Labs/organising OIE Ref. Lab.     |
|--|---|------------------|--|
| detection of influenza A virus by molecular test | participant   | 18               | OIE Reference laboratory for avian Influenza Padua Italy |

<sup>1</sup> validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

| Title of the project or contract   | Scope   | Name(s) of relevant OIE Reference Laboratories  |
|--|---|---|
| Next-generation Sequencing for genetic characterization of swine influenza viruses in Europe | The overall aim of the project is to validate the methods used for genetic characterisation of swine influenza A viruses (swIAV) in European pigs by next-generation sequencing (NGS) | Animal and Plant Health Agency New Haw, Addlestone Surrey KT15 3NB Weybridge UNITED KINGDOM |

**ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results**

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at:  
<http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

**ToR 12: To place expert consultants at the disposal of the OIE**

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report: